Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On ...

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on ...

Travere Therapeutics' stock has been volatile due to Filspari's failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price.

S hares of IBD 50 stock Travere Therapeutics plummeted Friday after the Food and Drug Administration accepted its review application for a rare kidney disease drug — with one caveat.

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the ...

Travere Therapeutics is a biopharmaceutical company headquartered in San Diego, California. Founded in 2008, the company develops therapies for rare kidney and metabolic conditions.

--Travere Therapeutics, Inc., today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET.. About ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) ‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to ...

Travere Therapeutics will host a conference call and webcast today, Thursday, September 5, 2024 at 6 p.m. ET to discuss the FDA full approval of FILSPARI.